Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.
Kavindya Fernando, Nilshan Fernando, Chiranthi Welhenge, Shashima Liyanage, B K T P Dayanath, Shamila De Silva, Chamila Mettananda
{"title":"Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.","authors":"Kavindya Fernando, Nilshan Fernando, Chiranthi Welhenge, Shashima Liyanage, B K T P Dayanath, Shamila De Silva, Chamila Mettananda","doi":"10.1186/s13063-025-08943-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most guidelines recommend high-intensity statins for the secondary prevention of acute coronary syndrome (ACS). However, several studies from other Asian populations suggest enhanced sensitivity to statins, with effective low-density lipoprotein cholesterol (LDL-C) reduction seen at lower doses and possible higher incidence of adverse effects at higher statin doses. However, there is no published data from Sri Lanka. Therefore, we aimed to explore this hypothesis by comparing the efficacy, safety and cost-effectiveness of atorvastatin at doses of 40 mg and 80 mg in a cohort of South Asian individuals presenting with ACS from Sri Lanka.</p><p><strong>Methods: </strong>This single-centre, prospective, randomised, controlled, open-label clinical trial is being conducted among patients naïve for statins admitted with incident ACS to a tertiary care setting in Sri Lanka. All patients will have LDL-C measured at baseline and are randomised to receive atorvastatin 40 mg or 80 mg in addition to standard of care. Data are collected using an interviewer-administered proforma. Patients are evaluated at 6, 12 and 24 weeks for adverse drug reactions and LDL-C level. The primary endpoint is the percentage of patients achieving LDL-C ≤ 70 mg/dL at 12 weeks. This outcome will be analysed by the intention-to-treat analysis. Secondary outcomes include safety assessments and a cost-effectiveness evaluation. For the latter, data on medication costs, including the number of tablets consumed, will be collected to calculate the average cost-effectiveness ratio and incremental cost-effectiveness ratio between the two dosing regimens.</p><p><strong>Discussion: </strong>This will be the first head-to-head comparison of atorvastatin 40 mg and 80 mg in a South Asian cohort. The findings will provide evidence on efficacy and safety of prescribing atorvastatin 40 mg dose in South Asians with ACS.</p><p><strong>Trial registration: </strong>Sri Lanka Clinical Trial Registry, SLCTR/2023/003. Registered on 03 March 2023, https://slctr.lk/trials/slctr-2023-003 .</p>","PeriodicalId":23333,"journal":{"name":"Trials","volume":"26 1","pages":"326"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403426/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13063-025-08943-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Most guidelines recommend high-intensity statins for the secondary prevention of acute coronary syndrome (ACS). However, several studies from other Asian populations suggest enhanced sensitivity to statins, with effective low-density lipoprotein cholesterol (LDL-C) reduction seen at lower doses and possible higher incidence of adverse effects at higher statin doses. However, there is no published data from Sri Lanka. Therefore, we aimed to explore this hypothesis by comparing the efficacy, safety and cost-effectiveness of atorvastatin at doses of 40 mg and 80 mg in a cohort of South Asian individuals presenting with ACS from Sri Lanka.
Methods: This single-centre, prospective, randomised, controlled, open-label clinical trial is being conducted among patients naïve for statins admitted with incident ACS to a tertiary care setting in Sri Lanka. All patients will have LDL-C measured at baseline and are randomised to receive atorvastatin 40 mg or 80 mg in addition to standard of care. Data are collected using an interviewer-administered proforma. Patients are evaluated at 6, 12 and 24 weeks for adverse drug reactions and LDL-C level. The primary endpoint is the percentage of patients achieving LDL-C ≤ 70 mg/dL at 12 weeks. This outcome will be analysed by the intention-to-treat analysis. Secondary outcomes include safety assessments and a cost-effectiveness evaluation. For the latter, data on medication costs, including the number of tablets consumed, will be collected to calculate the average cost-effectiveness ratio and incremental cost-effectiveness ratio between the two dosing regimens.
Discussion: This will be the first head-to-head comparison of atorvastatin 40 mg and 80 mg in a South Asian cohort. The findings will provide evidence on efficacy and safety of prescribing atorvastatin 40 mg dose in South Asians with ACS.
Trial registration: Sri Lanka Clinical Trial Registry, SLCTR/2023/003. Registered on 03 March 2023, https://slctr.lk/trials/slctr-2023-003 .
期刊介绍：
Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
